Form 8-K · Current report
Align Technology 8-K, filed Nov 6, 2026
- Filed
- CIK
- 0001097149
- Accession no.
- 0001097149-26-000085
Summary
Align Technology agreed to repurchase $270 million of its common stock from Goldman Sachs under an accelerated share repurchase agreement, with an initial delivery of about 1.44 million shares and settlement expected by December 29, 2026. The transaction is part of Align's $1.0 billion repurchase program and is expected to bring total 2026 share repurchases to about $500 million, CFO John Morici said.
Key points
- Align will prepay $270 million to Goldman Sachs and receive an initial delivery of approximately 1.44 million shares.
- The accelerated share repurchase is funded with cash on hand and expected to settle on or about December 29, 2026.
- Align expects approximately $330 million to remain available for future repurchases under its $1.0 billion program after the transaction.
- Align reported approximately $1.145 billion in cash and cash equivalents as of September 30, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 1.01Entry into a Material Definitive Agreement
- 2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
- 9.01Financial Statements and Exhibits
From the filing
Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Align Technology, Inc., a Delaware corporation (the “Company”), entered into an accelerated share repurchase agreement (the “ASR Contract”) with Goldman Sachs & Co. LLC (“Goldman Sachs”) to repurchase $270 million of the Company’s common stock authorized under the Company’s $1.0 billion stock repurchase program approved by the Company’s Board of Directors in April 2025 (the “Stock Repurchase Program”). The April 2025 program has $600 million remaining available for repurchase as of November 5, 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.